How Berns was paid
$4.6M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Paul L. BernsChief Executive Officer | $700,000 | $21,000 | $3,326,181 | $504,000 | $11,280 | $4,562,461 |
| Joshua Pinto, Ph.D.President | $645,000 | $989,350 | $4,643,438 | $464,400 | $1,050 | $6,743,238 |
| Bill Aurora, Pharm.D.Chief Strategy Officer | $545,000 | $870,219 | $1,553,896 | $323,594 | $9,291 | $3,302,000 |
| Henry O. GosebruchFormer President and Chief Executive Officer | $94,231 | $420,000 | $86,263 | — | $718,779 | $1,319,273 |
What changed and why
- $4.6MPaul L. Berns received total compensation of $4,562,461 in fiscal 2025, a decrease from the prior year total of $8,648,393.
- 120%Corporate goals under the 2025 performance-based cash bonus program were achieved at 120% and increased to 125% by the Board.
- $1.69In February 2025, Mr. Berns was granted an option to purchase 2,000,000 shares of common stock with an exercise price of $1.69.
- $0.72Stockholders approved the repricing of outstanding stock options to $0.72 per share during the 2025 annual meeting.
- $970KJoshua Pinto received a one-time cash signing bonus of $970,000 subject to repayment under specific conditions.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.